The immune response in HPV+ oropharyngeal cancer

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  King, Emma V ^a,b   Ottensmeier, Christian H ^a,c   Thomas, Gareth J ^a,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c Southampton NIHR Biomedical Research Unit in Nutrition Diet and Lifestyle   (United Kingdom)

Author keywords

Human papillomavirus; Oropharyngeal cancer; Prognosis; Survival; Tumor infiltrating lymphocytes

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PATIENT IDENTIFICATION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84899077860     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27254     Document Type: Article

References (10)

1. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009; 31:1393-422; PMID:19787782; http://dx.doi.org/10.1002/hed.21269.
2. Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, Clark JR, Milross CG, Kim J, O'Brien CJ, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010; 103:1510-7; PMID:20959828; http://dx.doi.org/10.1038/sj.bjc.6605944.
3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35; PMID:20530316; http://dx.doi. org/10.1056/NEJMoa0912217.
4. Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 2013; Forthcoming; http://dx.doi.org/10.1038/bjc.2013.639; PMID:24169344.
5. Heusinkveld M, Goedemans R, Briet RJ, Gelderblom H, Nortier JW, Gorter A, Smit VT, Langeveld AP, Jansen JC, van der Burg SH. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 2012; 131:E74-85; PMID:22020783; http://dx.doi. org/10.1002/ijc.26497.
6. Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, et al. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 2012; 72:5004-13; PMID:22991304; http://dx.doi.org/10.1158/0008-5472.CAN-11-3277.
7. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T. Microanatomical localization of PD-1 in human tonsils. Immunol Lett 2002; 83:215-20; PMID:12095712; http://dx.doi.org/10.1016/S0165-2478(02)00088-3.
8. Siegmund K, Rückert B, Ouaked N, Bürgler S, Speiser A, Akdis CA, Schmidt-Weber CB. Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. J Immunol 2009; 182:2124-30; PMID:19201865; http://dx.doi.org/10.4049/jimmunol.0802271.
9. Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2008; 27:1794-9; PMID:17828295; http://dx.doi.org/10.1038/sj.onc.1210798.
10. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005; 113:276-83; PMID:15386416; http://dx.doi.org/10.1002/ijc.20558.